Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immix Biopharma, Inc.

2.65
-0.0600-2.21%
Post-market: 2.650.00000.00%16:43 EDT
Volume:286.92K
Turnover:769.85K
Market Cap:73.81M
PE:-3.79
High:2.74
Open:2.70
Low:2.61
Close:2.71
Loading ...
Jun 23, 2025

Major Issues Report

Form 8-K - Current report
Jun 03, 2025

Major Issues Report

Form 8-K - Current report
May 19, 2025

[Rev.]Quaterly Report

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
May 19, 2025

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
May 09, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mar 25, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Nov 13, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 12, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 26, 2024

Major Issues Report

Form 8-K - Current report
Jul 22, 2024

Major Issues Report

Form 8-K - Current report
Jul 22, 2024

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Jun 14, 2024

Major Issues Report

Form 8-K - Current report
May 20, 2024

Major Issues Report

Form 8-K - Current report
May 09, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mar 29, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 17, 2024

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Feb 07, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 06, 2024

Major Issues Report

Form 8-K - Current report
Feb 05, 2024

Major Issues Report

Form 8-K - Current report
Nov 10, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]